Collegium Pharmaceutical, Inc.

Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older. Additionally, the company offers Karbinal ER, an oral carbinoxamine suspension for managing seasonal and perennial allergies. It also provides Poly-Vi-Flor and Tri-Vi-Flor, which are prescription vitamin supplements designed for infants and children with fluoride deficiencies. Other products include Tuzistra XR, a prescription cough suppressant oral suspension containing codeine polistirex and chlorpheniramine polistirex, and ZolpiMist, an oral spray indicated for addressing insomnia. Founded in 2015, the company was previously known as Aytu BioScience, Inc. before officially changing its name to Aytu BioPharma, Inc. in March 2021. Its corporate headquarters are located in Englewood, Colorado.

Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic Syndrome (LEMS). Catalyst also provides Ruzurgi, a specific treatment option for pediatric patients diagnosed with LEMS. Beyond its existing products, Catalyst is actively investigating additional applications for Firdapse, including its potential use in treating MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. The company engages in various strategic collaborations, such as licensing agreements with BioMarin Pharmaceutical Inc., and a joint development and commercialization agreement with Endo Ventures Limited concerning a generic version of Sabril tablets. Previously known as Catalyst Pharmaceutical Partners, Inc., the company adopted its current name in May 2015.

Elite Pharmaceuticals, Inc. (ELTP) is a specialized pharmaceutical company focused on the creation and manufacturing of generic medications, as well as oral, controlled-release drug formulations. Its business activities are primarily divided into two segments: Abbreviated New Drug Applications (ANDAs) for generic products and New Drug Applications (NDAs) for branded pharmaceuticals. The company's extensive product line includes drugs that it either owns, licenses, or produces through contract manufacturing. This portfolio features a variety of generic and oral-dose pharmaceutical products designed to address diverse medical needs. For instance, it offers Phentermine HCl 37.5mg tablets, marketed under the Adipex-P brand, and Phendimetrazine Tartrate 35mg tablets, known as Bontril, both utilized in bariatric medicine. Its offerings also extend to Naltrexone HCl 50mg tablets (Revia brand) for pain management, and Isradipine 2.5mg and 5mg capsules for cardiovascular conditions. Elite Pharmaceuticals further supplies various strengths of Oxycodone HCl immediate release tablets (5mg, 10mg, 15mg, 20mg, and 30mg) under the Roxycodone brand for pain relief, as well as Trimipramine Maleate Immediate Release antidepressant capsules (Surmontil brand). For central nervous system disorders, the company provides Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets, commonly associated with the Adderall brand. Additionally, its products include Dantrolene Sodium capsules (Dantrium brand) for muscle relaxation, SequestOX (an immediate-release Oxycodone formulation combined with Naltrexone), Loxapine Succinate capsules (Loxapine brand) for antipsychotic treatment, and a combination of Acetaminophen and Codeine Phosphate for managing mild to moderate pain, alongside various antibiotic products. Beyond its own product portfolio, Elite Pharmaceuticals also undertakes contract manufacturing of controlled-release products for external parties, covering therapeutic areas such as pain, allergies, bariatrics, and infections. The company is actively engaged in developing a new generation of opioid products specifically engineered to deter abuse. Established in 1997, Elite Pharmaceuticals, Inc. maintains its corporate headquarters in Northvale, New Jersey.

Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine). The company is also engaged in the advancement of CTx-2103, a candidate intended for the management of anxiety disorders. Founded in 2012, Cingulate Inc. maintains its corporate headquarters in Kansas City, Kansas.

Egalet Corporation is a fully integrated specialty pharmaceutical company headquartered in Pennsylvania focused on developing, manufacturing, and commercializing treatments.

Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical firm that specializes in developing therapeutic solutions through ribosome modulation. Its primary objective is to address rare and ultra-rare genetic diseases that arise from premature stop codons. The company's most advanced investigational compound, ELX-02, is currently progressing through Phase 2 clinical trials. This candidate is being evaluated for its potential to treat patients with cystic fibrosis and nephropathic cystinosis who possess diagnosed nonsense mutations. In addition to its lead program, Eloxx is actively pursuing several preclinical projects aimed at conditions like Alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis. The company also maintains various earlier-stage discovery initiatives focused on oncology. Eloxx Pharmaceuticals was established in 2013 and is headquartered in Watertown, Massachusetts.